• Explore /
  • Poster
  • / Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients.

Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients.

Abstract Poster

Authors

Edward Wolin

Edward M. Wolin

University of Kentucky, Lexington, KY

Edward M. Wolin , George A. Fisher Jr., Nilani Liyanage , Susan Pitman-Lowenthal , Beloo Mirakhur , Rodney F. Pommier , Montaser F. Shaheen , Aaron Vinik

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00774930

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 347)

DOI

10.1200/JCO.2018.36.4_suppl.347

Abstract #

347

Poster Bd #

G8

Abstract Disclosures

Similar Posters

First Author: George A. Fisher Jr.

First Author: Rodney F. Pommier

First Author: Aaron Vinik

First Author: Lowell Anthony